89396-94-1 Usage
Description
(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID is a complex organic compound with a unique structure and chirality. It is characterized by its imidazolidine-2,4-dione core, which is substituted with various functional groups, including an ethoxycarbonyl group, a phenylpropylamino group, and a propionyl group. (S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID exhibits specific stereochemistry, with all chiral centers having the S configuration.
Uses
Used in Pharmaceutical Industry:
(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID is used as an active pharmaceutical ingredient (API) for the development of drugs targeting specific biological pathways and receptors. Its unique structure and chirality may contribute to its selectivity and potency in modulating these targets, leading to potential therapeutic benefits.
Used as an Angiotensin Converting Enzyme (ACE) Inhibitor:
In the pharmaceutical industry, (S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID is used as an ACE inhibitor, which helps in the regulation of blood pressure by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This action leads to vasodilation and a reduction in blood pressure, making it a potential antihypertensive agent.
Used in Bioequivalence Testing:
(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID is also used as a reference standard in bioequivalence testing, specifically for the drug Imidapril hydrochloride. This testing is crucial in ensuring that generic versions of drugs are therapeutically equivalent to the original branded product, providing the same safety, efficacy, and quality.
Biochem/physiol Actions
Imidapril is a potent angiotensin converting enzyme inhibitor and anti-hypertensive.
Drug interactions
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: antagonism of hypotensive effect and
increased risk of renal impairment with NSAIDs;
hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia,
hypotension and renal failure with ARBs and
aliskiren.
Bee venom extract: possible severe anaphylactoid
reactions when used together.
Ciclosporin: increased risk of hyperkalaemia and
nephrotoxicity.
Cytotoxics: increased risk of angioedema with
everolimus.
Diuretics: enhanced hypotensive effect;
hyperkalaemia with potassium-sparing diuretics.
ESAs: increased risk of hyperkalaemia; antagonism
of hypotensive effect.
Gold: flushing and hypotension with sodium
aurothiomalate.
Lithium: reduced excretion, possibility of enhanced
lithium toxicity.
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and
nephrotoxicity.
Metabolism
Imidapril is a prodrug, and is metabolised in the liver
to the diacid imidaprilat, its active metabolite. The
bioavailability of imidaprilat is about 42% after oral doses
of imidapril.
About 40% of an oral dose is excreted in the urine, the
rest in the faeces.
Check Digit Verification of cas no
The CAS Registry Mumber 89396-94-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,3,9 and 6 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 89396-94:
(7*8)+(6*9)+(5*3)+(4*9)+(3*6)+(2*9)+(1*4)=201
201 % 10 = 1
So 89396-94-1 is a valid CAS Registry Number.
89396-94-1Relevant articles and documents
PROCESS FOR INDUSTRIALLY VIABLE PREPARATION OF IMIDAPRIL HYDROCHLORIDE
-
Page/Page column 9-10, (2008/06/13)
The invention relates to a novel method for the preparation of imidapril hydrochloride of formula-l by reacting esters of 4(S)-1-methyl-2-oxoimidazolidine-4-carboxylate of formula-ll with (S)-ethyl-2-[(S)-4-methyl-2,5-dioxooxazolidin-3-yl]-4-phenylbutanoate of formula-Ill and hydrolyzing the coupled product with an alcoholic hydrochloride.